4//SEC Filing
Morrow Phuong Khanh 4
Accession 0001209191-23-032250
CIK 0001674416other
Filed
May 24, 8:00 PM ET
Accepted
May 25, 5:35 PM ET
Size
9.4 KB
Accession
0001209191-23-032250
Insider Transaction Report
Form 4
Morrow Phuong Khanh
Chief Medical Officer
Transactions
- Tax Payment
Common Shares
2023-05-24$65.91/sh−2,527$166,555→ 4,411 total - Exercise/Conversion
Restricted Stock Units
2023-05-23+6,938→ 20,812 total→ Common Shares (6,938 underlying) - Exercise/Conversion
Common Shares
2023-05-23+6,938→ 6,938 total
Footnotes (3)
- [F1]The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]On May 23, 2022, the reporting person was granted 27,750 restricted stock units. On May 23, 2023, 6,938 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001928989
Filing Metadata
- Form type
- 4
- Filed
- May 24, 8:00 PM ET
- Accepted
- May 25, 5:35 PM ET
- Size
- 9.4 KB